Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer Head and Neck Clear all
Completed Phase 3 Interventional Results available

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02741570
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Nivolumab, Ipilimumab, Cetuximab/Erbitux, Cisplatin/Platinol, Carboplatin/Paraplatin, Fluorouracil/Adrucil
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 22, 2026, 3:53 PM EDT
Terminated Phase 2 Interventional Results available

Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer

NCT03938337
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cohort 1 Not Previously Treated, Cohort 2 Treated Previously
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Jul 22, 2026, 3:53 PM EDT
Completed Phase 1Phase 2 Interventional

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

NCT04742959
View directory record Official record
Conditions
Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
Interventions
TT-00420, Nab-Paclitaxel
Drug · Combination Product
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Jul 22, 2026, 3:53 PM EDT
Terminated Phase 1 Interventional

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

NCT03144661
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer, Ovarian Cancer, Solid Tumors
Interventions
INCB062079
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • New York, New York • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 3:53 PM EDT
Recruiting Phase 1 Interventional

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT05187182
View directory record Official record
Conditions
Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
Interventions
CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 22, 2026, 3:53 PM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02035527
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
sorafenib tosylate, cisplatin, docetaxel, Correlative Studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Jul 22, 2026, 3:53 PM EDT
Terminated No phase listed Observational

SCRI Tissue Testing Registry

NCT00965861
View directory record Official record
Conditions
Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
Interventions
Tissue Registry Study
Other
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Jul 22, 2026, 3:53 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

NCT06029270
View directory record Official record
Conditions
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Relatlimab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
83
States / cities
Dublin, California • Fremont, California • Fresno, California + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

NCT01612546
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Jul 22, 2026, 3:53 PM EDT
Recruiting Not applicable Interventional

High-Resolution PET-CT Imaging for Surgical Margin Visualization

NCT06915454
View directory record Official record
Conditions
Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Interventions
Intra-op PET/CT Specimen Scanner
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 22, 2026, 3:53 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

NCT00023790
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Jul 22, 2026, 3:53 PM EDT
Terminated Phase 1 Interventional Results available

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

NCT01012362
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer, Head and Neck Cancer, Kidney Cancer, Sarcoma, Hepatocellular Cancer
Interventions
Pazopanib, Ixabepilone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Jul 22, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer

NCT01843673
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
computed tomography, cone-beam computed tomography, radiography, electronic portal imaging, image-guided adaptive radiation therapy
Procedure · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 22, 2026, 3:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

NCT04424641
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
Interventions
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jul 22, 2026, 3:53 PM EDT
Completed No phase listed Observational

Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions

NCT00502580
View directory record Official record
Conditions
Oral Cancer
Interventions
Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Jul 22, 2026, 3:53 PM EDT
Not listed Phase 3 Interventional

Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer

NCT00022373
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Interventions
iseganan HCl oral solution, management of therapy complications
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Jul 22, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560

NCT04351373
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Fluorescein Sodium, YELLOW560 filter
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 22, 2026, 3:53 PM EDT
Terminated Phase 3 Interventional Results available

Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

NCT02137096
View directory record Official record
Conditions
Recurrent Nasopharynx Carcinoma
Interventions
Etoposide phosphate, Carboplatin, Ifosfamide, Autologous Stem Cell Transplantation
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Jul 22, 2026, 3:53 PM EDT
Completed Phase 1 Interventional

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

NCT04164069
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma
Interventions
Bevacizumab, Dasatinib, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Anne Noonan
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 22, 2026, 3:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

NCT04616196
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
NKTR-255, Cetuximab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 22, 2026, 3:53 PM EDT
Recruiting Phase 3 Interventional

Head and Neck Cancer Study Project in the Geriatric Population

NCT06998069
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Arm I Carboplatin, Paclitaxel, Pembrolizumab, Arm II Carboplatin, Paclitaxel, Cetuximab, Arm III Pembrolizumab
Drug
Lead sponsor
Brown University
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Jul 22, 2026, 3:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer

NCT01744340
View directory record Official record
Conditions
Head and Neck Cancer, Colon Cancer
Interventions
Head and neck, Colon- Closed as of May 2014
Drug
Lead sponsor
howard safran
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
The Bronx, New York • Pawtucket, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jul 22, 2026, 3:53 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

NCT04533750
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Positron Emission Tomography
Procedure · Other · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Results available

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

NCT03894618
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
SL-279252
Drug
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 22, 2026, 3:53 PM EDT